Clinical Trial Update: Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on pyrotinib as a neoadjuvant treatment for HER2-positive early breast cancer with non-objective response.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN